RIP2 enhances cell survival by activation of NF-ĸB in triple negative breast cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Receptor-interacting protein 2 (RIP2) is crucial for innate immunity and inflammation.
• Its role in cancer, particularly triple-negative breast cancer (TNBC), is under investigation.
• TNBC is an aggressive subtype with limited targeted therapy options.

Purpose of the Study:

• To investigate the role of RIP2 in TNBC chemoresistance and patient prognosis.
• To elucidate the molecular mechanisms by which RIP2 influences cancer cell survival.

Main Methods:

• Correlation analysis of RIP2 expression with patient prognosis and recurrence risk.
• Assessment of RIP2's effect on paclitaxel and ceramide-induced apoptosis in TNBC cells.
• Investigation of NF-κB signaling pathway activation and its downstream effects on cell survival proteins.

Main Results:

• High RIP2 expression in breast tumors correlates with poor prognosis and increased recurrence.
• RIP2 confers resistance to paclitaxel and ceramide-induced apoptosis in TNBC cells.
• RIP2 overexpression activates NF-κB, increasing pro-survival proteins and cell survival.
• RIP2 knockdown inhibits NF-κB, reduces anti-apoptotic proteins, and sensitizes cells to treatment.

Conclusions:

• RIP2 promotes breast cancer cell survival via NF-κB activation.
• Targeting RIP2 presents a potential therapeutic strategy for TNBC treatment.